Navigation Links
Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Date:11/6/2008

Supports safety of AHCC for cancer patients undergoing chemotherapy

PURCHASE, N.Y., Nov. 6 /PRNewswire/ -- A recently published study in the Journal of the Society for Integrative Oncology (Vol. 6, No. 3 (Summer), 2008: pp 105-109) by researchers at the University of Texas M.D. Anderson Cancer Center with the support of researchers from Amino Up Chemical Company in Sapporo, Japan has demonstrated that AHCC (Active Hexose Correlated Compound) can be safely used in combination with most chemotherapy agents. AHCC is a leading and commonly utilized dietary supplement for immune enhancement and cancer. The study was designed to determine on how AHCC interacts with select chemotherapy agents. As most chemotherapy agents undergo metabolism in the body through the CYP450 (Cytochrome P-450) pathway, this parameter was investigated in combination with four isoenzymes (3A4, 2C8, 2C9 and 2D6). This was followed by an evaluation of AHCC by including it as a substrate of these same isoenzymes.

The results of this in vitro metabolism study indicated that AHCC is not an inhibitor of the major CYP450 isoenzyme pathways. Therefore, AHCC is safe and unlikely to result in increased toxicity when used in combination with commonly used chemotherapeutic agents such as Cyclophosphamide, Ifosfamide, Paclitaxel, Docetaxel, Irinotecan, Vincristine, Interferon and Imatinib. It was demonstrated, that AHCC may have the potential for induce metabolism of drugs metabolized via the CYP450 2D6 pathway. Fortunately, the CYP450 2D6 is not a predominant pathway for metabolism of the most commonly used chemotherapy agents.

"Research shows that AHCC benefits cancer patients with its antitumor effects as well as its potential restorative effects on natural killer cells, macrophages and cytokines after anticancer chemotherapy," said Judith Smith, Pharm.D., BCOP,FCCP, FISOPP, Department of Gynecologic Oncology, Division of Surgery with The University of Texas M.D. Anderson Canc
'/>"/>

SOURCE AHCC Research Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
2. New Study Provides Key Findings for Biopharma Product Launch Evaluation
3. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
4. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
5. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
6. Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. Large-scale genetic study sheds new light on lung cancer
9. PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
10. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
11. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, Inc. ... advancing a new standard of respiratory critical care, will ... August 5, 2014 before the open of the ... will host a live teleconference and webcast at ... conference call, Discovery Labs, management will discuss the ...
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation (IMCL) ... medicine, treatment of infectious diseases as well as ... and prevention of pathologies like cardiovascular disease, Alzheimer,s ... 2014, ImmunoClin Corporation will complete the strategic relocation ... D.C. , a key center of North ...
(Date:7/29/2014)... 2014 Genera Energy Inc. ... innovation and supply chain advancements, has announced the ... Energy Grange™ and Supply ASSURE™. Both systems ... testing aimed at consolidating and simplifying the entire ... farmers and feedstock end users. , “Through the ...
(Date:7/29/2014)... July 29, 2014  United Therapeutics Corporation (NASDAQ: ... financial results for the second quarter ended ... shows that our medicines are reaching increasing ... hypertension (PAH)," said Martine Rothblatt, Ph.D., United ... commercial launch this quarter of our extended-release ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 24th Annual Roth ... takes place on Tuesday, March 13 at 2:00 p.m. Pacific ... webcast and may be accessed on the Company,s website at ...
... ATLANTA, March 7, 2012 Harriet L. Robinson, Ph.D., ... a biotech company specializing in the development of HIV/AIDS ... scientists may be one step closer to a vaccine ... study results were unveiled by Dr. Robinson during a ...
... BETHESDA, Md., March 7, 2012   Spherix Incorporated ... innovator in biotechnology for therapy in diabetes, metabolic ... regulatory consulting services to food, supplement, biotechnology and ... its drug candidates, SPX-106T, arrested development and reduced ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 2SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 3SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 4
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Business Intelligence (BI) Market 2014-2018" report to their ... The term BI refers to applications and ... or analyzing information about a company,s operations. BI help ... their business; for example, metrics on sales, production, and ...
(Date:7/29/2014)... of a stroke is an immensely complex challenge ... as effective therapy. Advancing such knowledge to improve ... focus of research by Sergei Adamovich, associate professor ... faculty more than a decade ago. It is ... from sources such as the National Institutes of ...
(Date:7/29/2014)... YORK , July 29, 2014  When it comes to ... new devices, if not the last. However, when it comes to ... Though the market for the Internet of Things and its ... make an impact in the healthcare industry, whether it,s in the ... to keep us fit. With that in mind, InformationWeek ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3
... 2013Dr. Carissa Klein of Australia was awarded the APEC ... by John Wiley & Sons, Inc., and Elsevier, on ... Research and Technology. Dr. Klein,s selection is ... Queensland that uniquely addresses the issue of sustainable ocean ...
... The strain of cholera that has sickened thousands in Haiti ... to the island over the past three years as some ... mBio , the online open-access journal of the American Society ... are consistent with earlier findings that indicate Vibrio cholerae ...
... TEMPE, Ariz -- Knowing virtually everything about how the ... for instance, precisely how particular cells develop into ... in understanding the basics of what drives biological processes. ... advances in medical science, bioengineering and related areas. ...
Cached Biology News:ASPIRE prize winner balances ocean conservation and socioeconomic viability 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 3Biomedical research revealing secrets of cell behavior 2
Request Info...
Prepared in distilled water....
... white. The extinction coefficient , E(1%) at ... phosphate-buffered saline, pH 7.4, containing ... 50% glycerol. Avidin (from egg white) is conjugated ... molecular sieving and is completely ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
Biology Products: